Daniel Guillen Mendoza
Neuromuscular Medicine · Memphis, TNNPI 1205219995
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by ITF Therapeutics LLC at 46.9% of the total. 2025 is the largest year on record at $54,422, more than ten times the $41 reported in 2019.
Across 121 payments — averaging $538.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITF Therapeutics LLC$31K
- Sarepta Therapeutics, Inc.$27K
- Novartis$5K
- Vertex$517
- NS Pharma, Inc.$371
- Neurelis, Inc.$253
- plus $1K from 14 others
Across 4 payments — averaging $4375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$18K
What the payments were for
- Consulting fees$26,06240%
- Speaking & faculty fees$27,84843%
- Travel & lodging$7,32811%
- Food & beverage$3,9286%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITF Therapeutics LLC | 25 | $30,537 |
| Sarepta Therapeutics, Inc. | 35 | $27,260 |
| Novartis | 8 | $4,749 |
| Vertex | 1 | $517 |
| NS Pharma, Inc. | 9 | $371 |
| Neurelis, Inc. | 8 | $253 |
| AstraZeneca | 2 | $234 |
| Biogen | 4 | $211 |
| UCB, Inc. | 8 | $199 |
| Catalyst Pharmaceuticals, Inc. | 4 | $183 |
| PTC Therapeutics, Inc. | 3 | $159 |
| Acadia Pharmaceuticals Inc | 2 | $157 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 3 | $156 |
| Biocodex, Inc. | 3 | $61 |
| Genentech USA, Inc. | 1 | $41 |
| Livanova USA, Inc. | 1 | $23 |
| SK Life Science, Inc. | 1 | $21 |
| Immedica Pharma US, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Akcea Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Other neuromuscular medicine in Memphis
- Elena CaronMemphis$2K
- Joshua AlpersChattanooga$623K
- Amanda PeltierNashville$235K
- Peter DonofrioNashville$47K
- Lindsay MalatestaNashville$24K
- Stephen LayfieldNashville$2K
- Madhura LayfieldNashville$2K
- John SturgisNashville$1K
- Christopher LeeNashville$379
- Joel TorresKnoxville$294
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.